CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
about
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsOverexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patientsNew advances in targeted gastric cancer treatmentFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerTargeting RTK Signaling Pathways in CancerRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsMany multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationSixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasiasFGF receptors: cancer biology and therapeuticsA novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceMolecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerRecent advances in antimultiple myeloma drug development.Polycomb target genes are silenced in multiple myeloma.Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myelomaA structure-guided approach to creating covalent FGFR inhibitorsTargeted therapies for adrenocortical carcinoma: IGF and beyond.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.Novel therapeutics in multiple myeloma.FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancerTargeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Urothelial tumorigenesis: a tale of divergent pathways.Molecular pathogenesis of multiple myeloma and its premalignant precursor.Genetic events in the pathogenesis of multiple myeloma.Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single-cell level.Clinical implications of chromosomal abnormalities in multiple myeloma.The role of microenvironment in tumor angiogenesis.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesA validated tumorgraft model reveals activity of dovitinib against renal cell carcinomaNew horizons in multiple myeloma therapy.Investigational treatments for multiple myeloma.
P2860
Q24617091-B40ED673-0297-4005-AC3D-F3ACDEE95B2BQ24670250-3C8E7115-E82F-4403-807D-3272818D01A4Q26738548-BE23BED5-6A91-4A3B-B55B-D6CEAB1918A6Q26764932-7F113EC1-9408-44B5-9B9A-A6E9CA08C0D8Q26781278-DB52A45C-5D29-441D-A873-9EDA7E3A9DB1Q26795594-18E06753-1FB5-4C00-9916-1293CEDA082AQ26852892-8AF38E1E-8292-4CCD-852A-90BEC4609D64Q27026205-83E0D730-8112-41FE-97F8-AD6D0B5AFABBQ27654979-B0B0AF0B-3CE8-4AFF-B8D1-F25958C492DDQ27851612-F3EF8382-EF74-4CAA-83B1-598085CDA02FQ28079309-D237EFB8-47CA-4A8D-8A60-68E4328AF2E3Q28252023-7007622B-BEE0-430A-A90A-80A9C63CFF48Q28291186-785AF7C0-73A1-4AF7-A3FE-88937B770F8AQ28395203-567FA46F-C863-4F8F-A8F2-AB96B7E161F3Q30433431-BE6585F3-9641-4E30-A27B-829D2AA18A24Q33292711-59F12B69-1C0C-4D82-86A1-747474B51D48Q33416297-A4E2E3E0-1AA2-4753-9AAA-BB25B1B7E2A9Q33633898-5FBE1C55-B318-4493-AEE5-6DAC38A70162Q33697369-F5D46B74-FFD7-46BE-AA50-3AD0B4020FE9Q33845985-E08602E2-B24B-4E6E-AE31-C46B12835E37Q34061522-A51ED443-6772-40BB-9A92-B37E50846B7FQ34101433-12D0B1F8-3734-448A-80D6-D96ABE1A6BC5Q34241661-AC9C2826-E883-4156-BB5E-FD92C3DF508DQ34542012-449EFCBE-CC86-4901-AC84-CA95AEA99ED0Q34637538-3D3D1AA7-8AE1-46F2-8A4C-C774702C1CBCQ34733972-FC2CF2AB-3006-472C-A0CF-88752333AA70Q35017004-BE802AC8-35E8-491D-9AFA-1D94BFB8200FQ35055386-684E3EB9-1A09-497E-A08F-15520A65440EQ35597799-1D377552-4013-418C-8D40-693DC57F24D0Q35878807-E0869487-FA93-4E55-86FF-0208AEA5B654Q36234720-CBA11AFF-3349-43A2-B873-F1A19395F783Q36290238-B6747B67-5C2D-4FAB-8649-4D95D363A5E2Q36380235-4680357B-BE60-45A4-98C4-BDCC7BEC136EQ36453377-E874E58A-1CDF-4064-9D46-DDE90650483DQ36497416-D96B331D-8103-4D4A-93A5-AB256C3F75E1Q36558575-F49CF274-7943-4049-B55D-7380A00E7708Q36602853-8BD0D7CA-F5A3-46DB-A3EF-CC86B6A30E63Q36606040-975CD221-184E-42C9-893F-5486E916CEBAQ36636660-E35D03BA-1A04-4AA9-83E4-926FAB8F1FDBQ36654336-E4EDC9DE-0176-4B42-A545-DCA97946A487
P2860
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
CHIR-258, a novel, multitarget ...... t of t(4;14) multiple myeloma.
@en
type
label
CHIR-258, a novel, multitarget ...... t of t(4;14) multiple myeloma.
@en
prefLabel
CHIR-258, a novel, multitarget ...... t of t(4;14) multiple myeloma.
@en
P2093
P1433
P1476
CHIR-258, a novel, multitarget ...... t of t(4;14) multiple myeloma.
@en
P2093
A Keith Stewart
Carla Heise
Christine Chen
Donna Reece
Hong Chang
Marion Wiesmann
Zhi Hua Li
P304
P356
10.1182/BLOOD-2004-10-3913
P407
P577
2004-12-14T00:00:00Z